MOLECULAR MECHANISMS OF PCP AND SIGMA DRUG ACTION
PCP 和 Sigma 药物作用的分子机制
基本信息
- 批准号:2872055
- 负责人:
- 金额:$ 23.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1991
- 资助国家:美国
- 起止时间:1991-06-01 至 2002-01-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION:
Physiological effects produced by ingestion of the drug of abuse
phencyclidine (PCP) are mediated by PCP acting through several receptors,
ion channels, and neurotransmitter reuptake transporters. Among the
receptors activated by PCP is the sigma receptor, located in motor and
limbic areas of rodent, non-human primate, and human brains. In rodent
striatum, nucleus accumbens, prefrontal cortex, hippocampus and cerebellum,
we have shown that one role of the sigma receptors is regulation of
catecholamine release. The catecholamine dopamine is critical to
reinforcement, movement, and psychosis; the catecholamine norepinephrine is
involved in mood stability, attention, and cognition. Interference with
these neurotransmitter systems by PCP acting through the sigma receptor
might be expected to contribute to the psychosis and dysphoria resulting
from PCP abuse. Several second messengers involved in the stimulation of
catecholamine release from brain tissue and cells have been identified, but
nothing is known about the signal transduction pathways mediating sigma
receptor inhibition of catecholamine release. In this project, the
relationships among sigma receptor agonist binding, activation or inhibition
of second messengers, and release of catecholamines will be established in
cell models, including the human neuroblastoma cells SK-N-SH and SH-SY5Y for
studies on regulation of norepinephrine release, and in rat pheochromocytoma
(PC12) cells for regulation of dopamine release. These cell lines have
proved valuable in understanding catecholamine release mechanisms in the
past, and many second messenger systems have been studied in them. In some
experiments not involving catecholamine release, we will use rat neonatal
cerebellar granule cells in culture. We have used this cell type
extensively to study sigma-1 receptor inhibition of arachidonic acid
release. Sigma receptors of the sigma-1 subtype are thought to be coupled
to their transducers via a G protein. By using antisense oligonucleotides
to the alpha subunits of various inhibitory G proteins, we have begun to
identify G protein(s) involved in sigma-1-mediated responses. The
physiological relevance of the identified second messengers coupling sigma
receptors to catecholamine release in cell models will be determined in
brain slices using our established superfusion methodologies. Our findings
should be helpful in designing appropriate therapies for abuse of PCP, and
related psychotic syndromes.
描述:
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LINDA L WERLING其他文献
LINDA L WERLING的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LINDA L WERLING', 18)}}的其他基金
MOLECULAR MECHANISM OF PCP- AND SIGMA-DRUG ACTIONS
PCP 和 Sigma 药物作用的分子机制
- 批准号:
2118861 - 财政年份:1991
- 资助金额:
$ 23.22万 - 项目类别:
MOLECULAR MECHANISM OF PCP- AND SIGMA-DRUG ACTIONS
PCP 和 Sigma 药物作用的分子机制
- 批准号:
3461256 - 财政年份:1991
- 资助金额:
$ 23.22万 - 项目类别:
MOLECULAR MECHANISM OF PCP- AND SIGMA-DRUG ACTIONS
PCP 和 Sigma 药物作用的分子机制
- 批准号:
3461254 - 财政年份:1991
- 资助金额:
$ 23.22万 - 项目类别:
MOLECULAR MECHANISM OF PCP- AND SIGMA-DRUG ACTIONS
PCP 和 Sigma 药物作用的分子机制
- 批准号:
3461255 - 财政年份:1991
- 资助金额:
$ 23.22万 - 项目类别:
MOLECULAR MECHANISMS OF PCP AND SIGMA DRUG ACTION
PCP 和 Sigma 药物作用的分子机制
- 批准号:
6350483 - 财政年份:1991
- 资助金额:
$ 23.22万 - 项目类别:
MOLECULAR MECHANISM OF PCP- AND SIGMA-DRUG ACTIONS
PCP 和 Sigma 药物作用的分子机制
- 批准号:
2118862 - 财政年份:1991
- 资助金额:
$ 23.22万 - 项目类别:
MOLECULAR MECHANISMS OF PCP AND SIGMA DRUG ACTION
PCP 和 Sigma 药物作用的分子机制
- 批准号:
6150462 - 财政年份:1991
- 资助金额:
$ 23.22万 - 项目类别:
MOLECULAR MECHANISMS OF PCP AND SIGMA DRUG ACTION
PCP 和 Sigma 药物作用的分子机制
- 批准号:
2406369 - 财政年份:1991
- 资助金额:
$ 23.22万 - 项目类别:
相似海外基金
DA/PCP RECEPTOR INHERITANCE: CLASSICAL GENETIC ANALYSIS
DA/PCP 受体遗传:经典遗传分析
- 批准号:
2117880 - 财政年份:1994
- 资助金额:
$ 23.22万 - 项目类别:
U.S-France Joint Seminar: Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neural Modulation and Protection, Montpellier, France, September 1991
美法联合研讨会:多重 Sigma 和 PCP 受体配体:神经调节和保护机制,法国蒙彼利埃,1991 年 9 月
- 批准号:
9015992 - 财政年份:1991
- 资助金额:
$ 23.22万 - 项目类别:
Standard Grant
DRUG DEVELOPMENT OF SELECTIVE PCP RECEPTOR LIGANDS
选择性五氯苯酚受体配体的药物开发
- 批准号:
2118616 - 财政年份:1990
- 资助金额:
$ 23.22万 - 项目类别:
DEVELOPMENT OF SELECTIVE PCP RECEPTOR LIGANDS
选择性 PCP 受体配体的开发
- 批准号:
2118613 - 财政年份:1990
- 资助金额:
$ 23.22万 - 项目类别:
DRUG DEVELOPMENT OF SELECTIVE PCP RECEPTOR LIGANDS
选择性五氯苯酚受体配体的药物开发
- 批准号:
2331142 - 财政年份:1990
- 资助金额:
$ 23.22万 - 项目类别:
DRUG DEVELOPMENT OF SELECTIVE PCP RECEPTOR LIGANDS
选择性五氯苯酚受体配体的药物开发
- 批准号:
2118615 - 财政年份:1990
- 资助金额:
$ 23.22万 - 项目类别:
DEVELOPMENT OF SELECTIVE PCP RECEPTOR LIGANDS
选择性 PCP 受体配体的开发
- 批准号:
3212948 - 财政年份:1990
- 资助金额:
$ 23.22万 - 项目类别:
PCP RECEPTOR CHARACTERIZATION WITH NEW AFFINITY LIGANDS
用新亲和配体表征 PCP 受体
- 批准号:
3213399 - 财政年份:1990
- 资助金额:
$ 23.22万 - 项目类别:
PCP RECEPTOR CHARACTERIZATION WITH NEW AFFINITY LIGANDS
用新亲和配体表征 PCP 受体
- 批准号:
3213401 - 财政年份:1990
- 资助金额:
$ 23.22万 - 项目类别:
DEVELOPMENT OF SELECTIVE PCP RECEPTOR LIGANDS
选择性 PCP 受体配体的开发
- 批准号:
3212946 - 财政年份:1990
- 资助金额:
$ 23.22万 - 项目类别:














{{item.name}}会员




